Recombinant

Risankizumab (IL23A) – Research Grade Biosimilar

CATALOG NUMBER: 10-735

Clonality:
Recombinant Monoclonal
Conjugate:
Unconjugated
Specifications
source-species:
CHO cells
source-species:
CHO cells
Immunogen:
Humanized / IL23A [Homo sapiens]
Conjugate:
Unconjugated
Purification:
>95%
Clonality:
Recombinant Monoclonal
Isotype:
IgG1-kappa
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Storage Conditions:
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for 1-2 weeks. Store at -20 °C for 12 months. Store at -80 °C for long term storage.
Additional Names:
BI 655066,risankizumab-rzaa
User Note:
Optimal dilutions for each application to be determined by the researcher.
Background:
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.

FOR RESEARCH USE ONLY

For additional information, visit ProSci’s Terms & Conditions Page.

Disclaimer:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

CATALOG NUMBER:

10-735

List Size:
0.1 mg

List Price:

$515.00

Shipping Info
Customize your order
Custom Antibody Services

New & Featured Products

CATALOG NUMBER: PM-7369-HRP

CATALOG NUMBER: PM-7369-biotin

CATALOG NUMBER: PM-7369